These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 28296619)

  • 1. Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilar.
    Kim S; Song J; Park S; Ham S; Paek K; Kang M; Chae Y; Seo H; Kim HC; Flores M
    MAbs; 2017; 9(4):704-714. PubMed ID: 28296619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Demonstrating Analytical Similarity of Trastuzumab Biosimilar HLX02 to Herceptin
    Xie L; Zhang E; Xu Y; Gao W; Wang L; Xie MH; Qin P; Lu L; Li S; Shen P; Jiang W; Liu S
    BioDrugs; 2020 Jun; 34(3):363-379. PubMed ID: 32072477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses.
    Lee J; Kang HA; Bae JS; Kim KD; Lee KH; Lim KJ; Choo MJ; Chang SJ
    MAbs; 2018; 10(4):547-571. PubMed ID: 29482416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drifts in N-Linked Glycosylation Result in ADCC Potency Variation of Perjeta® from August 2020 to October 2021 in China.
    Yao B; Zhang D; Cao W; Yang G; Li W; Hui X; Ouyang P; Chen G; Liu B
    Biomed Res Int; 2022; 2022():7868391. PubMed ID: 35535043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological Characterization of SB3, a Trastuzumab Biosimilar, and the Influence of Changes in Reference Product Characteristics on the Similarity Assessment.
    Lee JH; Paek K; Moon JH; Ham S; Song J; Kim S
    BioDrugs; 2019 Aug; 33(4):411-422. PubMed ID: 31190280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of Structural and Functional Comparability of Biosimilar Products: Trastuzumab as a Case Study.
    Joshi S; Rathore AS
    BioDrugs; 2020 Apr; 34(2):209-223. PubMed ID: 31975160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate.
    Chen L; Wang L; Shion H; Yu C; Yu YQ; Zhu L; Li M; Chen W; Gao K
    MAbs; 2016 Oct; 8(7):1210-1223. PubMed ID: 27380163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physicochemical and biological characterization of SB2, a biosimilar of Remicade® (infliximab).
    Hong J; Lee Y; Lee C; Eo S; Kim S; Lee N; Park J; Park S; Seo D; Jeong M; Lee Y; Yeon S; Bou-Assaf G; Sosic Z; Zhang W; Jaquez O
    MAbs; 2017; 9(2):364-382. PubMed ID: 28005456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physicochemical and biological characterization of a biosimilar trastuzumab.
    López-Morales CA; Miranda-Hernández MP; Juárez-Bayardo LC; Ramírez-Ibáñez ND; Romero-Díaz AJ; Piña-Lara N; Campos-García VR; Pérez NO; Flores-Ortiz LF; Medina-Rivero E
    Biomed Res Int; 2015; 2015():427235. PubMed ID: 26075238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparability of Antibody-Mediated Cell Killing Activity Between a Proposed Biosimilar RTXM83 and the Originator Rituximab.
    Cuello HA; Segatori VI; Alberto M; Pesce A; Alonso DF; Gabri MR
    BioDrugs; 2016 Jun; 30(3):225-31. PubMed ID: 27053342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Charge variant analysis of proposed biosimilar to Trastuzumab.
    Dakshinamurthy P; Mukunda P; Prasad Kodaganti B; Shenoy BR; Natarajan B; Maliwalave A; Halan V; Murugesan S; Maity S
    Biologicals; 2017 Mar; 46():46-56. PubMed ID: 28087106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the Molecular Mechanism of Action of SB3, a Trastuzumab Biosimilar.
    Paek K; Kim GW; Ahn SY; Lim JH; Jung D; Kim S; Lee JH
    BioDrugs; 2019 Dec; 33(6):661-671. PubMed ID: 31549311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic Comparability of a Biosimilar Trastuzumab Anticipated from Its Physicochemical and Biological Characterization.
    Miranda-Hernández MP; López-Morales CA; Piña-Lara N; Perdomo-Abúndez FC; Pérez NO; Revilla-Beltri J; Molina-Pérez A; Estrada-Marín L; Flores-Ortiz LF; Ruiz-Argüelles A; Medina-Rivero E
    Biomed Res Int; 2015; 2015():874916. PubMed ID: 26682224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing Analytical and Functional Similarity of Proposed Amgen Biosimilar ABP 980 to Trastuzumab.
    Hutterer KM; Polozova A; Kuhns S; McBride HJ; Cao X; Liu J
    BioDrugs; 2019 Jun; 33(3):321-333. PubMed ID: 30972630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of high mannose levels in N-linked glycosylation through cell culture process conditions to increase antibody-dependent cell-mediated cytotoxicity activity for an antibody biosimilar.
    Rameez S; Gowtham YK; Nayar G; Mostafa SS
    Biotechnol Prog; 2021 Sep; 37(5):e3176. PubMed ID: 34021724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosimilars lining up to compete with Herceptin--opportunity knocks.
    Nelson KM; Gallagher PC
    Expert Opin Ther Pat; 2014 Nov; 24(11):1149-53. PubMed ID: 25307085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilarity assessment of biosimilar therapeutic monoclonal antibodies.
    Ishii-Watabe A; Kuwabara T
    Drug Metab Pharmacokinet; 2019 Feb; 34(1):64-70. PubMed ID: 30600193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The criticality of high-resolution N-linked carbohydrate assays and detailed characterization of antibody effector function in the context of biosimilar development.
    Brady LJ; Velayudhan J; Visone DB; Daugherty KC; Bartron JL; Coon M; Cornwall C; Hinckley PJ; Connell-Crowley L
    MAbs; 2015; 7(3):562-70. PubMed ID: 25898160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®.
    Lee C; Jeong M; Lee JJ; Seo S; Cho SC; Zhang W; Jaquez O
    MAbs; 2017; 9(6):968-977. PubMed ID: 28640663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of FcγRIIIA effector cells used in in vitro ADCC bioassay: Comparison of primary NK cells with engineered NK-92 and Jurkat T cells.
    Hsieh YT; Aggarwal P; Cirelli D; Gu L; Surowy T; Mozier NM
    J Immunol Methods; 2017 Feb; 441():56-66. PubMed ID: 27939300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.